{"organizations": [], "uuid": "078a78d87891b31a39c1e10c4b13b3b806d201cc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/public/resources/images/BN-XN922_3nKsJ_TOP_20180220034013.jpg", "site_section": "https://www.wsj.com/europe", "section_title": "The Wall Street Journal &amp; Breaking News, Business, Financial and Economic News, World News and Video", "url": "https://www.wsj.com/articles/biogen-ceo-calls-share-slump-an-overreaction-to-alzheimers-trial-1519118911", "country": "US", "domain_rank": 387, "title": "Biogen CEO Calls Share Slump an Overreaction to Alzheimer’s Trial", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.146, "site_type": "news", "published": "2018-02-20T12:28:00.000+02:00", "replies_count": 0, "uuid": "078a78d87891b31a39c1e10c4b13b3b806d201cc"}, "author": "Peter Landers", "url": "https://www.wsj.com/articles/biogen-ceo-calls-share-slump-an-overreaction-to-alzheimers-trial-1519118911", "ord_in_thread": 0, "title": "Biogen CEO Calls Share Slump an Overreaction to Alzheimer’s Trial", "locations": [], "entities": {"persons": [{"name": "michel vounatsos", "sentiment": "none"}], "locations": [{"name": "tokyo", "sentiment": "none"}, {"name": "mass.", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}, {"name": "cambridge", "sentiment": "none"}], "organizations": [{"name": "biogen inc.", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "TOKYO—Biogen Inc.’s chief executive said investors overreacted when they pushed down the company’s share price nearly 7% on news that it was adding patients to trials of an Alzheimer’s disease drug.\n“It’s very common that we have to increase the sample size, and we don’t take that as a sign that influences whatsoever the outcome of the study,” said Michel Vounatsos, head of the Cambridge, Mass., drugmaker, in an interview on a visit to Japan, where Biogen is trying to expand its presence.\n... To Read the Full Story Subscribe Sign In", "external_links": [], "published": "2018-02-20T12:28:00.000+02:00", "crawled": "2018-02-21T04:00:29.001+02:00", "highlightTitle": ""}